Advertisement

Psychoactive Drugs in the Psychotic and Affective Disorders

  • Alice Medalia
  • James Gold
Part of the Critical Issues in Neuropsychology book series (CINP)

Abstract

The neuropsychological assessment of psychiatric patients is often complicated by the medications or treatments that are being administered. The clinician must discern whether impaired test performance reflects disease-related or iatrogenically induced cognitive deficit. In this chapter we review the literature investigating the effects of neuroleptics, antidepressants, and lithium on the neuropsychological test performance of psychiatric patients. For a review of the cognitive effects of these medications in normal subjects we refer the reader to Judd, Squire, Butters, Salmon, and Palier (1987). This review focuses on measures that are commonly used in the context of neuropsychological assessment. It is organized by medication and particular cognitive function or test that might be affected. At the end of each section we propose some clinical guidelines and theoretical hypotheses that can be generated on the basis of this literature.

Keywords

Schizophrenic Patient Psychoactive Drug Bipolar Patient Digit Symbol Chronic Schizophrenia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Aaronson, B. S. (1963). The comparative sensitivity of the qualitative and quantitative Porteus Maze scores to drug effects. Journal of Clinical Psychology, 19, 184–185.PubMedCrossRefGoogle Scholar
  2. Abrams, J. (1958). Chlorpromazine in the treatment of chronic schizophrenia. Diseases of the Nervous System, 19, 20–28.PubMedGoogle Scholar
  3. Amin, M. M., Khan, P., & Lehman, H. E. (1980). The differential effects of viloxazine and imipramine on performance tests: Their relationship to behavioral toxicity. Psychopharmacology Bulletin, 16, 57–60.PubMedGoogle Scholar
  4. Aylward, E., Walker, E., & Bettes, B. (1984). Intelligence in schizophrenia: Meta-analysis of the research. Schizophrenia Bulletin, 10, 430–459.PubMedCrossRefGoogle Scholar
  5. Bajor, G. F. (1977). Memory loss with lithium. American Journal of Psychiatry, 134, 588.PubMedGoogle Scholar
  6. Baldessarini, R. J. (1977). Chemotherapy in psychiatry. Cambridge, Mass.: Harvard University Press.Google Scholar
  7. Bellini, L., Gambini, O., Palladino, F., & Scarone, S. (1988). Neuropsychological assessment of functional central nervous system disorders. I. Hemispheric functioning characteristics in schizophrenia and affective illness. Acta Psychiatrica Scandinavic, 78, 242–246.CrossRefGoogle Scholar
  8. Braff, D. L., Glick, I. D., Johnson, M. H., & Zisook, S. (1988). The clinical significance of thought disorder across time in psychiatry patients. Journal of Nervous and Mental Disease, 176, 213–220.PubMedCrossRefGoogle Scholar
  9. Brooks, G., & Weaver, L. (1961). Some relations between psychiatric and psychomotor behavior changes associated with tranquilizing medications. Comprehensive Psychiatry, 2, 203–210.PubMedCrossRefGoogle Scholar
  10. Byrne, D. G. (1976). Choice reaction times in depressive states. British Journal of Social and Clinical Psychology, 15, 149–156.PubMedCrossRefGoogle Scholar
  11. Calev, A. (1984). Recall and recognition in mildly disturbed schizophrenics: The use of matched tasks. Psychological Medicine, 14, 425–429.PubMedCrossRefGoogle Scholar
  12. Calev, A., Venables, P. H., & Monk, A. F. (1983). Evidence for distinct verbal memory pathologies in severely and mildly disturbed schizophrenics. Schizophrenia Bulletin, 9, 247–264.PubMedCrossRefGoogle Scholar
  13. Calev, A., Ben Tzvi, E., Shapira, B., Drexler, H., Carasso, R., & Lerer, B. (1989). Distinct memory impairments following electroconvulsive therapy and imipramine. Psychological Medicine, 19, 111–119.PubMedCrossRefGoogle Scholar
  14. Castner, C. W, Covington, C. M., & Nickols, J. E. (1958). The effects of a Thorazine-centered treatment program with psychological evaluations. Texas Report of Biological Medicine, 16, 21–30.Google Scholar
  15. Cawley, R. H., Post, F., & Whitehead, A. (1973). Barbiturate tolerance and psychological functioning in elderly depressed patients. Psychological Medicine, 3, 39–52.PubMedCrossRefGoogle Scholar
  16. Christodoulou, G. N., Kokkevi, A., Lykouras, E. P., Stefanis, C. N., & Papadimitriou, G. N. (1981). Effects of lithium on memory. American Journal of Psychiatry, 138, 847–848.PubMedGoogle Scholar
  17. Clark, M. L., Ray, T. S., & Ragland, R. E. (1963). Chlorpromazine in chronic schizophrenic women: Rate of onset and rate of dissipation of drug effects. Psychosomatic Medicine, 3, 212–217.Google Scholar
  18. Clemmesen, L. (1988). Anticholinergic side-effects of antidepressants: Studies of the inhibition of salivation. Acta Psychiatrica Scandinavica Supplement 345, 78, 90–93.CrossRefGoogle Scholar
  19. Cohen, R. M., Weingartner, H., Smallberg, S. A., Pickar, D., & Murphy, D. L. (1982). Effort and cognition in depression. Archives of General Psychiatry, 39, 593–597.PubMedCrossRefGoogle Scholar
  20. Coppen, A. (1978). Lithium and memory impairment. Lancet, 1, 448.PubMedCrossRefGoogle Scholar
  21. Coughlan, A. K., & Hollows, S. E. (1984). Use of memory tests in differentiating organic disorder from depression. British Journal of Psychiatry, 145, 164–167.PubMedCrossRefGoogle Scholar
  22. Demers, R. G., & Heninger, G. R. (1971). Visual-motor performance during lithium treatment: A preliminary report. Journal of Clinical Psychopharmacology, 11, 274–279.Google Scholar
  23. Depue, R. A., Dubicki, M. D., & McCarthy, T. (1975). Differential recovery of intellectual, associational, and psychophysiological functioning in withdrawn and active schizophrenics. Journal of Abnormal Psychology, 84, 325–330.PubMedCrossRefGoogle Scholar
  24. Donnelly, E. F., Waldman, I., Murphy, D. L., Wyatt, R. J., & Goodwin, F. K. (1980). Primary affective disorder: Thought disorder in depression. Journal of Abnormal Psychology, 89, 315–319.PubMedCrossRefGoogle Scholar
  25. Donnelly, E. E, Murphy, D. L., Goodwin, F., & Waldman, I. (1982). Intellectual function in primary affective disorder. British Journal of Psychiatry, 140, 633–636.PubMedCrossRefGoogle Scholar
  26. Elass, P., Mellerup, E. T., Rafaelsen, O. J., & Theilgaard, A. (1981). Effect of lithium on reaction time—A study of diurnal variations. Psychopharmacology, 72, 279–282.CrossRefGoogle Scholar
  27. Elwan, Q, Souief, M., Hassan, M. A., & Allam, M. (1976). Psychometric assessment of the therapeutic efficacy of antidepressant agents. Journal of International Medical Research, 4, 118–124.PubMedGoogle Scholar
  28. Engelsmann, F., Katz, J., Ghadirian, A. M., & Schachter, D. (1988). Lithium and memory: A long-term follow-up study. Journal of Clinical Psychopharmacology, 8, 207–212.PubMedCrossRefGoogle Scholar
  29. Fennig, S., Levine, Y, Naisberg, S., & Elizur, A. (1986). The effect of trihexyphenidyl (Artane) on memory in schizophrenic patients. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 11, 71–78.CrossRefGoogle Scholar
  30. Finn, M. H. P., Nadolski, F., Guy, W., & Gross, M. (1955). Clinical, psychological, and myoneural changes in psychotic patients under oral Serpasel medication. Journal of Nervous and Mental Disease, 122, 458–467.PubMedCrossRefGoogle Scholar
  31. Fredericks, R. S., & Finkel, P. N. (1978). Schizophrenic performance on the Halstead-Reitan Battery. Journal of Clinical Psychology, 34, 26–30.PubMedCrossRefGoogle Scholar
  32. Friedman, A. S., Granick, S., Cohen, H. W., & Cowitz, B. (1966). Imipramine (Tofranil) vs. placebo in hospitalized psychotic depressives. Journal of Psychiatry Research, 4, 13–36.CrossRefGoogle Scholar
  33. Fromm, D, & Schopflocher, D. (1984). Neuropsychological test performance in depressed patients before and after drug therapy. Biological Psychiatry, 19, 55–71.PubMedCrossRefGoogle Scholar
  34. Fromm-Auch, D. (1983). Neuropsychological assessment of depressed patients before and after drug therapy: Clinical profile interpretation. In P. Flor-Henry & J. Gruzelier (Eds.), Laterality and psychopathology (pp. 83–102). Amsterdam: Elsevier.Google Scholar
  35. Ghadirian, A. M., Engelsmann, F., & Amanth, J. (1983). Memory functions during lithium therapy. Journal of Clinical Psychopharmacology, 3, 313–315.PubMedCrossRefGoogle Scholar
  36. Gibbs, J. J., Wilkens, B., & Lauterbach, C. G. (1957). A controlled clinical psychiatric study of the drug chlorpromazine. Journal of Clinical and Experimental Psychopathology, 18, 269–283.PubMedGoogle Scholar
  37. Gilgash, C. A. (1961). Thorazine therapy with catatonic schizophrenics in relation to Wechsler verbal and performance subtest comparison. Journal of Clinical Psychology, 17, 95.PubMedCrossRefGoogle Scholar
  38. Glass, R. M., Uhlenhuth, E. H., Hartel, F. W, Matuzas, W, & Fischman, M. W (1981). Cognitive dysfunction and imipramine in outpatient depressives. Archives of General Psychiatry, 38, 1048–1051.PubMedCrossRefGoogle Scholar
  39. Gold, J., & Hurt, S. (1990). The effects of haloperidol on thought disorder and IQ in schizophrenia. Journal of Personality Assessment, 54, 390–400.PubMedCrossRefGoogle Scholar
  40. Goldberg, E. (1985). Akinesia, tardive dysmentia, and frontal lobe disorders in schizophrenia. Schizophrenia Bulletin, 11, 255–263.PubMedCrossRefGoogle Scholar
  41. Goode, D. J., Manning, A. A., Middleton, J. F., & Williams, B. (1981). Fine motor performance before and after treatment in schizophrenic and schizoaffective patients. Psychiatry Research, 5, 247–255.PubMedCrossRefGoogle Scholar
  42. Heaton, R. K., & Crowley, T. J. (1981). Effects of psychiatric disorders and their somatic treatment on neuropsychological test results. In S. B. Filskov & T. B. Boll (Eds.), Handbook of clinical neuropsychology (pp. 481–525). New York: Wiley.Google Scholar
  43. Heilizer, F. (1959). The effects of chlorpromazine on psychomotor and psychiatric behavior of chronic schizophrenic patients. Journal of Nervous and Mental Disease, 128, 358–364.PubMedGoogle Scholar
  44. Held, J. M., Cromwell, R. L., Frank, E. T., Jr., & Fann, W E. (1970). Effects of phenothiazines on reaction time in schizophrenics. Journal of Psychiatric Research, 7, 209–213.PubMedCrossRefGoogle Scholar
  45. Henry, G. M., Weingartner, H., & Murphy, D. L. (1973). Influence of affective states and psychoactive drugs on verbal learning and memory. American Journal of Psychiatry, 130, 966–971.PubMedGoogle Scholar
  46. Hitri, A., Craft, R. B., Fallon, J., Sethi, R., & Sinha, D. (1987). Serum neuroleptic and anticholinergic activity in relationship to cognitive toxicity of antiparkinsonian agents in schizophrenic patients. Psychopharmacology Bulletin, 23, 33–37.PubMedGoogle Scholar
  47. Howard, M. L., Hogan, T. P., & Wright, M. W. (1975). The effects of drugs on psychiatric patients’ performance on the Halstead-Reitan Neuropsychological Test Battery. Journal of Nervous and Mental Disease, 161, 166–171.PubMedCrossRefGoogle Scholar
  48. Joffe, R. T., MacDonald, C., & Kutcher, S. R (1988). Lack of differential cognitive effects of lithium and carbamazepine in bipolar affective disorder. Journal of Clinical Psychopharmacology, 8, 425–428.PubMedCrossRefGoogle Scholar
  49. Jones, B. R, Henderson, M., & Welch, C. A. (1988). Executive functions in unipolar depression before and after electroconvulsive therapy. International Journal of Neuroscience, 38, 287–297.PubMedCrossRefGoogle Scholar
  50. Judd, L. L. (1979). Effect of lithium on mood, cognition and personality function in normal subjects. Archives of General Psychiatry, 36, 860–865.PubMedCrossRefGoogle Scholar
  51. Judd, L. L., Hubbard, B., Janowsky, D. S., Huey, L. Y, & Takahashi, K. I. (1977). The effect of lithium carbonate on the cognitive functions of normal subjects. Archives of General Psychiatry, 34, 355–357.PubMedCrossRefGoogle Scholar
  52. Judd, L. L., Squire, L. R., Butters, N., Salmon, D. P., & Palier, K. A. (1987). Effects of psychotropic drugs on cognition and memory in normal humans and animals. In H. Y. Meltzer (Ed.), Psychopharmacology: The third generation of progress (pp. 1467–1475). New York: Raven Press.Google Scholar
  53. Judson, A. J., & MacCasland, B. W. (1960). The effects of chlorpromazine on psychological test scores. Journal of Consulting Psychology, 24, 192.CrossRefGoogle Scholar
  54. Kendrick, D. C., & Moyes, I. C. A. (1979). Activity, depression, medication and performance on the Revised Kendrick Battery. British Journal of Social and Clinical Psychology, 18, 341–350.PubMedCrossRefGoogle Scholar
  55. Kendrick, D. C., & Post, F. (1967). Differences in cognitive status between healthy, psychiatrically ill, and diffusely brain-damaged elderly subjects. British Journal of Psychiatry, 113, 75–81.PubMedCrossRefGoogle Scholar
  56. Kenning, I. S., Richardson, N. L., & Tucker, F. G. (1960). The treatment of depressive states with imipramine hydrochloride. Canadian Psychiatric Association Journal, 5, 60–64.PubMedGoogle Scholar
  57. Killian, G., Holzman, P., Davis, J. M., & Gibbons, R. (1984). Effects of psychotropic medication on selected cognitive and perceptual measures. Journal of Abnormal Psychology, 93, 58–70.PubMedCrossRefGoogle Scholar
  58. Koh, S. D. (1978). Remembering of verbal materials by schizophrenic young adults. In S. Schwartz (Ed.), Language and cognition in schizophrenia (pp. 59–99). Hillsdale, N.J.: Erlbaum.Google Scholar
  59. Koh, S. D, Grinker, R. R., Sr., Marasarz, T. Z., & Forman, R L. (1981). Affective memory and schizophrenic anhedonia. Schizophrenia Bulletin, 7, 292–307.PubMedCrossRefGoogle Scholar
  60. Kopelman, M. D. (1986). Clinical tests of memory. British Journal of Psychiatry, 148, 517–525.PubMedCrossRefGoogle Scholar
  61. Kornetsky, C. (1972). The use of a simple test of attention as a measure of drug effects in schizophrenic patients. Psychopharmacologia, 24, 99–106.PubMedCrossRefGoogle Scholar
  62. Kornetsky, C., Pettit, M., Wynne, R., & Evarts, E. V. (1959). A comparison of the psychological effects of acute and chronic administration of chlorpromazine and secobarbital in schizophrenic patients. Journal of Mental Science, 105, 190–198.PubMedGoogle Scholar
  63. Kovitz, B., Carter, J. T., & Addison, W. P. (1955). A comparison of chlorpromazine and reserpine in chronic psychosis. A.M.A. Archives of Neurology and Psychiatry, 74, 467–471.PubMedCrossRefGoogle Scholar
  64. Kusumo, K. S., & Vaughn, M. (1977). Effects of lithium salts on memory. British Journal of Psychiatry, 131, 453–457.PubMedCrossRefGoogle Scholar
  65. Legg, J. S., & Stiff, M. P. (1976). Drug related test patterns of depressed patients. Psychopharmacology, 50, 205–210.PubMedCrossRefGoogle Scholar
  66. Lloyd, D. N., & Newbrough, J. R. (1964). Sensory changes with phenothiazine medication in schizophrenic patients. Journal of Nervous and Mental Disease, 139, 169–175.PubMedCrossRefGoogle Scholar
  67. Loo, H., Bonnel, J., Etevenon, P., Benyacoub, J., & Slowen, P. (1981). Intellectual efficiency in manicdepressive patients treated with lithium. Acta Psychiatrica Scandinavic, 64, 423–430.CrossRefGoogle Scholar
  68. Lovett Doust, J. W, Lewis, D. J., Miller, A., Sprott, D, & Wright, R. L. D (1959). Controlled assessment of antidepressant drugs, including Tofranil. Canadian Psychiatric Association Journal, 4, S190–194.Google Scholar
  69. Malone, J. R. L., & Hemsley, D. R. (1977). Lowered responsiveness and auditory signal detectabilty during depression. Psychological Medicine, 7, 717–722.PubMedCrossRefGoogle Scholar
  70. Marder, S. R., Asarnow, R. F., & Van Putten, T. (1984). Information processing and neuroleptic response in acute and stabilized schizophrenic patients. Psychiatry Research, 13, 41–49.PubMedCrossRefGoogle Scholar
  71. Marusarz, T. Z., Wolpert, E. A., & Koh, S. D. (1981). Memory processing with lithium carbonate. Journal of Clinical Psychiatry, 42, 190–192.PubMedGoogle Scholar
  72. Mason-Browne, N. O., & Borthwick, J. W. (1957). The effects of perphenazine (Trilafon) on modification of crude consciousness. Diseases of the Nervous System, 18, 300–306.PubMedGoogle Scholar
  73. McCreadie, R. G., & Morrison, D. P. (1985). The impact of lithium in south-west Scotland. I. Demographic and clinical findings. British Journal of Psychiatry, 146, 70–80.PubMedCrossRefGoogle Scholar
  74. Medalia, A., Gold, J., & Merriam, A. (1988). The effects of neuroleptics on neuropsychological test results of schizophrenics. Journal of Clinical Neuropsychology, 3, 249–271.Google Scholar
  75. Meltzer, H. Y, Kane, J. M., & Kolakowska, T. (1983). Plasma levels of neuroleptics, prolactin levels, and clinical response. In J. T. Coyle & S. J. Enna (Eds.), Neuroleptics: Neurochemical, behavioral, and clinical perspectives (pp. 255–280). New York: Raven Press.Google Scholar
  76. Muller-Oerlinghausen, B., Bauer, H., Girke, W., Kanowski, S., & Gonclaves, N. (1977). Impairment of vigilance and performance under lithium-treatment. Studies in patients and normal volunteers. Pharmakopsychiatrie-Neuropsychopharmakologie, 10, 67–78.CrossRefGoogle Scholar
  77. Neuchterlein, K. H., & Dawson, M. E. (1984). Information processing and attentional functioning in the developmental course of schizophrenic disorders. Schizophrenia Bulletin, 10, 160–03.CrossRefGoogle Scholar
  78. Oltmanns, T. F., Ohayon, J., & Neale, J. M. (1979). The effect of medication and diagnostic criteria on distractibility in schizophrenia. Journal of Psychiatric Research, 14, 81–91.CrossRefGoogle Scholar
  79. Orzack, M. H., Kornetsky, C., & Freeman, H. (1967). The effects of daily administration of carphenazine on attention in the schizophrenic patient. Psychopharmacologia, 11, 31–38.PubMedCrossRefGoogle Scholar
  80. Pearl, D. (1962). Phenothiazine effects in chronic schizophrenia. Journal of Clinical Psychology, 18, 86–89.PubMedCrossRefGoogle Scholar
  81. Perlick, D, Stastny, P., Katz, I., Mayer, M., & Mattis, S. (1986). Memory deficits and anticholinergic levels in chronic schizophrenia. American Journal of Psychiatry, 143, 230–232.PubMedGoogle Scholar
  82. Petrie, A., & Le Beau, J. (1956). Psychological changes in man after chlorpromazine and certain types of brain surgery. Journal of Clinical and Experimental Psychopathology, 17, 170–179.PubMedGoogle Scholar
  83. Pishkin, V (1962). CPT and VCRT performances as functions of imipramine and nialamide. Journal of Clinical Psychology, 18, 83–86.PubMedCrossRefGoogle Scholar
  84. Porteus, S. D. (1957). Maze test reactions after chlorpromazine. Journal of Consulting Psychology, 21, 15–20.PubMedCrossRefGoogle Scholar
  85. Porteus, S. D., & Barclay, J. E. (1957). A further note on chlorpromazine: Maze reactions. Journal of Consulting Psychology, 21, 297–299.PubMedCrossRefGoogle Scholar
  86. Preodor, D., Wolpert, G. Y, Ostrow, D., Holinger, P., & Wolpert, E. A. (1977). Memory loss with lithium treatment. American Journal of Psychiatry, 134, 1047–1048.PubMedGoogle Scholar
  87. Pugh, L. A. (1968). Response time and electrodermal measure in chronic schizophrenia: The effects of chlorpromazine. Journal of Nervous and Mental Disease, 146, 62–70.PubMedCrossRefGoogle Scholar
  88. Rapp, M. S., & Thomas, M. R. (1979). Lithium and memory loss. Canadian Journal of Psychiatry, 24, 700–701.Google Scholar
  89. Raskin, A., Friedman, A. S., & DiMascio, A. (1983). Effects of chlorpromazine, imipramine, diazepam, and phenelzine on psychomotor and cognitive skills of depressed patients. Psychopharmacology Bulletin, 19, 649–652.Google Scholar
  90. Ray, T. S., Ragland, R. E., & Clark, M. L. (1964). Chlorpromazine in chronic schizophrenic women: Comparison of different effects on various psychological modalities during and after treatment. Journal of Nervous and Mental Disease, 138, 348–353.PubMedCrossRefGoogle Scholar
  91. Reus, V, Targum, S. D., Weingartner, H., & Post, R. M. (1979). Effect of lithium carbonate on memory processes of bipolar affectively ill patients. Psychopharmacology, 63, 39–42.PubMedCrossRefGoogle Scholar
  92. Riddle, M., & Roberts, A. H. (1978). Psychosurgery and the Porteus Maze Tests. Archives of General Psychiatry, 35, 493–497.PubMedCrossRefGoogle Scholar
  93. Rogers, D, Lees, A. J., Smith, E., Trimble, M., & Stern, G. M. (1987). Bradyphrenia in Parkinson’s disease and psychomotor retardation in depressive illness. Brain, 110, 761–776.PubMedCrossRefGoogle Scholar
  94. Rosofsky, I., Levin, S., & Holzman, P. S. (1982). Psychomotility in the functional psychosis. Journal of Abnormal Psychology, 91, 71–74.PubMedCrossRefGoogle Scholar
  95. Savard, R. J., Rey, A. C., & Post, R. M. (1980). Halstead-Reitan Category Test in bipolar and unipolar affective disorders. Journal of Nervous and Mental Disease, 168, 297–304.PubMedCrossRefGoogle Scholar
  96. Schooler, N. R., & Goldberg, S. C. (1972). Performance tests in a study of phenothiazines in schizophrenia: Caveats and conclusions. Psychopharmacologia, 24, 81–98.PubMedCrossRefGoogle Scholar
  97. Schou, M. (1968). Lithium in psychiatric therapy and prophylaxis. Journal of Psychiatric Research, 6, 67–95.PubMedCrossRefGoogle Scholar
  98. Seppala, T., Linnoila, M., & Mattila, M. J. (1978). Psychomotor skills in depressed outpatients treated with L-tryptophan, doxepin or chlormipramine. Annals of Clinical Research, 10, 241–221.Google Scholar
  99. Serafetinides, E. A., & Clark, M. L. (1973). Psychological effects of single dose antipsychotic medication. Biological Psychiatry, 7, 263–267.PubMedGoogle Scholar
  100. Serafetinides, E. A., Collins, S., & Clark, M. L. (1972). Haloperidol, clopenthixol, and chlorprom-azine in chronic schizophrenia. Journal of Nervous and Mental Disease, 154, 31–42.PubMedCrossRefGoogle Scholar
  101. Shatin, L., Rockmore, L., & Funk, I. C. (1956). Response of psychiatric patients to massive doses of Thorazine: II. Psychological test performance and comparative drug evaluation. Psychiatric Quarterly, 30, 402–416.PubMedCrossRefGoogle Scholar
  102. Shaw, E. D., Stokes, P. E., Mann, J. J., & Manevitz, A. Z. A. (1987). Effects of lithium carbonate on the memory and motor speed of bipolar outpatients. Journal of Abnormal Psychology, 96, 64–69.PubMedCrossRefGoogle Scholar
  103. Silberman, E. K., Weingartner, H., & Post, R. M. (1983). Thinking disorder in depression. Archives of General Psychiatry, 40, 775–780.PubMedCrossRefGoogle Scholar
  104. Simon, S. H. (1967). Effects of tranquilizers on the Trail Making Test with chronic schizophrenics. Journal of Consulting Psychology, 31, 322–323.PubMedCrossRefGoogle Scholar
  105. Small, I. E, Small, J. G., Milstein, V, & Moore, J. E. (1972). Neuropsychological observations with psychosis and somatic treatment. Journal of Nervous and Mental Disease, 155, 6–13.PubMedCrossRefGoogle Scholar
  106. Smigan, L., & Penis, C. (1983). Memory functions and prophylactic treatment with lithium. Psychological Medicine, 13, 529–536.PubMedCrossRefGoogle Scholar
  107. Snow, L. H., & Rickels, K. (1964). The controlled evaluation of imipramine and amitriptyline in hospitalized depressed psychiatric patients. Psychopharmacologia, 5, 409–416.PubMedCrossRefGoogle Scholar
  108. Spiegal, D. E., & Spiegal, P. K. (1967). The effects of carphenazine, trifluoperazine, and chlorpromazine on ward behavior, physiological functioning, and psychological test scores in chronic schizophrenic patients. Journal of Nervous and Mental Disease, 144, 111–116.CrossRefGoogle Scholar
  109. Spohn, H. E., LaCoursiere, R. B., Thompson, K., & Coyne, L. (1977). phenothiazine effect son psychological and physiological dysfunction in chronic schizophrenics. Archives of General Psychiatry, 34, 633–644.PubMedCrossRefGoogle Scholar
  110. Spohn, H. E., Coyne, L., LaCoursiere, R., Mazur, D., & Hayes, K. (1985). Relation of neuroleptic dose and tardive dyskinesia to attention, information-processing, and psychophysiology in mediated schizophrenics. Archives of General Psychiatry, 42, 849–859.PubMedCrossRefGoogle Scholar
  111. Squire, L. R., Judd, L. L., Janowsky, D. S., & Huey, L. Y (1980). Effects of lithium carbonate on memory and other cognitive functions. American Journal of Psychiatry, 137, 1042–1046.PubMedGoogle Scholar
  112. Staton, R. D., Wilson, H., & Brumback, R. A. (1981). Cognitive improvement associated with tricyclic antidepressant therapy. International Journal of Neuroscience, 24, 307–312.Google Scholar
  113. Sternberg, D. E., & Jarvik, M. E. (1976). Memory functions in depression. Archives of General Psychiatry, 33, 219–224.PubMedCrossRefGoogle Scholar
  114. Strauss, M., Lew, M., Coyle, J., & Tune, L. (1985). Psychopharmacologic and clinical correlates of attention in chronic schizophrenia. American Journal of Psychiatry, 142, 497–499.PubMedGoogle Scholar
  115. Telford, R., & Worrall, E. P. (1978). Cognitive functions in manic-depressives: Effects of lithium and physostigmine. British Journal of Psychiatry, 133, 424–428.PubMedCrossRefGoogle Scholar
  116. Tourlentes, T. T., Hunsiker, A. L., & Hurd, D. E. (1958). Chlorpromazine and communication processes. Archives of Neurology and Psychiatry, 79, 468–472.PubMedCrossRefGoogle Scholar
  117. Tune, L., Strauss, M., Lew, M., Breitlinger, E., & Coyle, J. T. (1982). Serum levels of anticholinergic drugs and impaired recent memory in chronic schizophrenic patients. American Journal of Psychiatry, 139, 1460–1462.PubMedGoogle Scholar
  118. Walker, E. (1981). Attentional and neuromotor functions of schizophrenics, schizoaffectives, and patients with other affective disorders. Archives of General Psychiatry, 38, 1355–1358.PubMedCrossRefGoogle Scholar
  119. Walker, E., & Green, M. (1982). Motor proficiency and attentional task performance of psychotic patients. Journal of Abnormal Psychology, 91, 261–268.PubMedCrossRefGoogle Scholar
  120. Walker, E., & Shaye, J. (1982). Familial schizophrenia: A predictor of neuromotor and attentional abnormalities in schizophrenia. Archives of General Psychiatry, 39, 1153–1156.PubMedCrossRefGoogle Scholar
  121. Weaver, L. A., & Brooks. G. W. (1961). The effects of drug-induced Parkinsonism on the psychomotor performance of chronic schizophrenics. Journal of Nervous and Mental Disease, 133, 148–154.PubMedCrossRefGoogle Scholar
  122. Weckowicz, T. E., Tarn, C. N. I., Mason, J., & Bay, K. S. (1978). Speed in test performance in depressed patients. Journal of Abnormal Psychology, 87, 578–582.PubMedCrossRefGoogle Scholar
  123. Whitehead, W. A., & Thune, L. E. (1958). The effects of chlorpromazine on learning in chronic psychotics. Journal of Consulting Psychology, 22, 379–383.PubMedCrossRefGoogle Scholar
  124. Wilson, H., & Staton, R. D. (1984). Neuropsychological changes in children associated with tricyclic antidepressant therapy. International Journal of Neuroscience, 24, 307–312.CrossRefGoogle Scholar
  125. Winter, W. D., & Frederickson, W. (1956). The short-term effects of chlorpromazine on psychiatric patients. Journal of Consulting Psychology, 20, 431–434.PubMedCrossRefGoogle Scholar
  126. Wittenborn, J. R., Plante, M., Burgess, F., & Livermore, N. (1961a). The efficacy of electroconvulsive therapy, iproniazid and placebo in the treatment of young depressed women. Journal of Nervous and Mental Disease, 133, 316–332.PubMedCrossRefGoogle Scholar
  127. Wittenborn, J. R., Plante, M., Burgess, F., & Maurer, H. (1961b). A comparison of imipramine, electroconvulsive therapy and placebo in the treatment of depressions. Journal of Nervous and Mental Disease, 135, 131–137.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1992

Authors and Affiliations

  • Alice Medalia
    • 1
  • James Gold
    • 2
  1. 1.Departments of Psychiatry and Neurology, Albert Einstein College of MedicineBronx Municipal Hospital CenterBronxUSA
  2. 2.Department of PsychologyNational Institute of Mental Health, St. Elizabeths HospitalUSA

Personalised recommendations